EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance

Masataka Kuwana iD, Naonobu Sugiyama, Shigeki Momohara, Tatsuya Atsumi, Syuji Takei, Naoto Tamura iD, Masayoshi Harigai iD, Takao Fujii, Hiroaki Matsuno, Tsutomu Takeuchi, Kazuhiko Yamamoto, Yoshinari Takasaki und 7 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/road063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Masataka Kuwana und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Piperidines, Pyrimidines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We evaluated the real-world safety/effectiveness of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), in patients with RA in Japan registered in a post-marketing surveillance study.

Methods

This interim analysis included data from July 2013 to December 2018. Adverse events (AEs), serious AEs (SAEs), Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)/Disease Activity Score in 28 joints, erythrocyte sedimentation rate [DAS28-4(ESR)] scores, and rates of SDAI/CDAI/DAS28-4(ESR)-defined remission and low disease activity were analysed using 6 months of data. Risk factors for serious infections were assessed by multivariable analyses.

Results

Safety and disease activity were evaluated in 6866 and 6649 patients, respectively. Overall, 32.73%/7.37% of patients reported AEs/SAEs. Clinically important AEs with tofacitinib included serious infections/infestations [3.13% of patients; incidence rate (IR; patients with events) 6.91/100 patient-years (PY)], herpes zoster (3.63%; IR 8.02/100 PY), and malignancies (0.68%; IR 1.45/100 PY). SDAI/CDAI/DAS28-4(ESR) scores and remission/low disease activity rates improved over 6 months. Male sex, older age, Steinbrocker’s stage IV, history of infection, and diabetes mellitus at baseline were independent risk factors for serious infection.

Conclusions

In patients with RA receiving tofacitinib in Japan, safety was consistent with the reported profile, and disease activity improved over 6 months. Study identifier NCT01932372.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsPiperidinesPyrimidinesHumansMaleJapanPyrrolesProduct Surveillance, PostmarketingTreatment Outcome

Stichwörter der Autor:innen

Janus kinase inhibitorpost-marketing surveillancerheumatoid arthritissafetytofacitinib

Substanzen

tofacitinibPyrrolesAntirheumatic AgentsPiperidinesPyrimidines

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Kusanagi Orthopedic Rheumatology Clinic, Shizuoka, Japan.
  • Department of Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan.
  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Pediatric Rheumatology, Medical Center for Children, Kagoshima University Hospital, Kagoshima, Japan.

ORCID-Profile: Masataka Kuwana, Naoto Tamura, Masayoshi Harigai, Michiaki Takagi

Zitieren

APA

Kuwana, M., Sugiyama, N., Momohara, S., Atsumi, T., Takei, S., Tamura, N., Harigai, M., Fujii, T., Matsuno, H., Takeuchi, T., Yamamoto, K., Takasaki, Y., Tanigawa, M., Endo, Y., Hirose, T., Morishima, Y., Yoshii, N., Mimori, T., & Takagi, M. (2024). Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Modern Rheumatology. https://doi.org/10.1093/mr/road063

Vancouver

Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N, et al. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Modern Rheumatology. 2024. doi:10.1093/mr/road063

BibTeX
@article{Kuwana2024,
  author = {Kuwana, Masataka and Sugiyama, Naonobu and Momohara, Shigeki and Atsumi, Tatsuya and Takei, Syuji and Tamura, Naoto and Harigai, Masayoshi and Fujii, Takao and Matsuno, Hiroaki and Takeuchi, Tsutomu and Yamamoto, Kazuhiko and Takasaki, Yoshinari and Tanigawa, Miki and Endo, Yutaka and Hirose, Tomohiro and Morishima, Yosuke and Yoshii, Noritoshi and Mimori, Tsuneyo and Takagi, Michiaki},
  title = {Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road063}
}
Kostenlos starten →